This post was originally published on this site

Nearly two years ago, Nessan Bermingham, Ph.D., handed the reins of Intellia Therapeutics over to John Leonard, M.D., the R&D chief who had built the company alongside him. After a break, he landed at Atlas Venture, the VC firm that helped launch Intellia in 2014 and that is now debuting Korro Bio, Bermingham’s latest project. Read more.

The post Atlas unveils RNA-editing Korro Bio helmed by Nessan Bermingham appeared first on Atlas Venture.